The Latest Cardiac and Vascular News
Leading Developer of Regenerative Cardiovascular Products to Complete FDA Clinical Trial and Advance Other Technologies in Treatment of Heart Disease ATLANTA, July 27, 2021 /PRNewswire/ — CorMatrix® Cardiovascular, Inc., (www.cormatrix.com) is a leading developer of regenerative cardiovascular products and is working on a portfolio of groundbreaking regenerative heart valve products for individuals with valve […]
ATLANTA, Aug. 5, 2020 /PRNewswire/ — CorMatrix® Cardiovascular, Inc., (www.cormatrix.com) a leading developer of regenerative biomaterial compositions and medical devices, today announced European Patent Office patent claim allowances for European Community (EC) Patent Application Nos. 15 902 462.9 and 15 886 687.1, and U.S. Patent and Trademark Office patent claim allowance for U.S. Patent […]
ATLANTA, Feb. 7, 2020 /PRNewswire/ — CorMatrix®Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced receiving FDA approval to expand and enroll 20 additional patients in the adult arm, including up to 4 additional cardiac surgery research and investigative centers, for its early feasibility IDE study of the Cor® TRICUSPID ECM® valve* for […]
ATLANTA, Jan. 28, 2020 /PRNewswire/ — CorMatrix® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announces the first minimally invasive robotic implant of Cor® PATCH by Dr. Husam H. Balkhy, Professor of Surgery, and Director of Robotic and Minimally Invasive Cardiac Surgery at the University of Chicago Medicine. Dr. Balkhy is a global leader […]
ATLANTA, Sept. 26, 2019 /PRNewswire/ — CorMatrix® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced it has completed enrollment of the adult arm of its FDA early feasibility IDE study for the Cor® TRICUSPID ECM® cardiac valve* for adults with endocarditis and for pediatric patients with congenital heart valve disease. The Cor® TRICUSPID ECM® valve […]
ATLANTA, June 11, 2019 /PRNewswire/ — CorMatrix® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced FDA 510(k) clearance for the Cor™ PATCH. The Cor™ PATCH is indicated for epicardial tissue support and repair in adult patients. The Cor™ PATCH epicardial patch is the first epicardial cardiovascular medical device composed of first next […]
INDIANAPOLIS, Feb. 21, 2019 /PRNewswire/ — A patient who received a first-in-the-world tricuspid valve procedure as part of a new national clinical trial at Franciscan Health Heart Center is home and recovering well. The procedure utilizes a revolutionary material called extracellular matrix. The material provides a seamless valve structure which engages and […]
ATLANTA, Jan. 24, 2019 /PRNewswire/ — CorMatrix® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced FDA approval of an early feasibility study IDE to evaluate the safety and feasibility of the Cor™ TRICUSPID ECM® cardiac valve for adults with endocarditis and for pediatric patients with congenital heart valve disease. The […]
SILVER SPRING, Md.–(BUSINESS WIRE)–Aziyo Biologics, Inc. a fully integrated regenerative medicine company, today announced it has completed an asset purchase agreement with CorMatrix� Cardiovascular, Inc. for the purchase of all CorMatrix commercial assets and related intellectual property. With the acquisition, Aziyo will: Add 5 commercially marketed products Double topline revenue Add […]
